1Steller MA.Update on human papillomavirus vaccines for cervical cancer[J].Curr Opin Investig Drugs,2002;3(1):37
2Davidson EJ,Kitchener HC,Stern PL.The use of vaccines in the prevention and treatment of cervical cancer[J]. Clin Oncol,2002;14(3):193～200
3Kaufmann AM,Stern PL,Rankin EM,et al.Safety and immunogenicity of TA-HPV,a recombinant vaccinia virus expressing modified human papillomavirus(HPV)-16 and HPV-18 E6 and E7 genes,in women with progressive cervical cancer[J]. Clin Cancer Res,2002;8(12):3676～3685
4Pilch H,Hoehn H,Schmidt M,et al.CD8^+ CD45RA^+ CD27-CD28-T-cell subset in PBL of cervical cancer patients representing CD8+T-cells being able to recognize cervical cancer associated antigens provided by HPV 16 E7[J]. Zentralbl Gynakol,2002;124(8～9):406～412
5Einstein MH,Goldberg GL.Human papillomavirus and cervical neoplasia[J]. Cancer Invest,2002;20(7～8):1080～1085
6Santin AD,Hermonat PL,Ravaggi A,et al.Induction of human papillomavirus-specific CD4^+ and CD8^+ lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer[J]. J Virol,1999;73(7):5402～5410
8Frazer I.Vaccines for papillomavirus infection[J]. Virus Res,2002;89(2):271～274
9Kim TY,Myoung HJ,Kim JH,et al.Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16(E6/E7)immortalized tumor cells:involvement of CD4+ and CD8+T cells in protection[J].Cancer Res,2002;62(24):7234～7240
10Mauriizo R,Schultz J.Success of vaccine offers promise of cervical cancer prevention[J]. J Natl Cancer Inst,2003;95(2):102～104
